Rezolute Inc

NASDAQ:RZLTUnited States

Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.

Contact Information

Headquarters

275 Shoreline Drive, Suite 500REDWOOD CITY, CA, United States 94065

Phone

650-206-4507

Fax

302-636-5454

Executives

Acting Chairman of the Board, Chief Executive Officer

Nevan Elam

Chief Financial Officer

Daron Evans

Chief Medical Officer

Brian Roberts

Director

Young-Jin Kim

Independent Director

Philippe Fauchet